The medical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s showing significant promise in clinical trials for addressing obesity. Unlike some available weight loss approaches, retatrutide appears to deliver a significant substantial loss in body weight and benefit metabolic function, particu